摘要
目的:分析影响丙戊酸钠血药浓度监测结果的因素,为丙戊酸钠的合理使用提供参考。方法:采用酶增强免疫分析法监测丙戊酸钠的血药浓度,分析监测结果与病人的年龄、性别、疗效、用药剂量间的关系。结果:在监测的158例病人中,丙戊酸钠血药浓度<50、50～100、>100μg/ml的病例数分别为69例(43.67%)、70例(44.30%)和19例(12.03%),控制癫发作的总有效率分别为36.23%、87.14%和78.94%。血药浓度<50μg/ml组与50～100μg/ml组和>100μg/ml组之间,服药剂量<400mg/d组与400～800mg/d、>800mg/d组之间,疗效有显著性差异(P<0.01)。不同年龄组,不同性别组之间,血药浓度监测结果的差异没有统计学意义(P>0.05)。结论:临床应根据血药浓度监测结果个体化给药。
Objective： To analyze the influencial factors of serum concentrations of sodium valproate in epilepsy patients,so as to provide reference for rational use of sodium valproate. Methods： Serum concentrations of sodium valproate were deter- mined by enzyme enhancement immunoassay technique. The relationships of serum concentrations of sodium valproate,age and gender of patients,therapeutic effectiveness and dosages were analyzed. Results： In the 158 cases, the eoncentrations of sodium valproate which were 〈50,50-100,〉100 μg/ml accounted for 69（43.67%） ,70（44.30%） ,19（12. 03%） and the total effective rates were 36.32 %, 87. 14 %,78.94%, respectively. The effectiveness were significantly different among different serum concentration groups（〈50,50-100,〉100 μg/ml）,and different dose groups（〈400,400-800,〉800 mg/d）. There was no statistical difference between male and female patients, or among different age groups. Conclusion： It is necessary to make out individual therapeutic regimens of sodium valproate according to results of serum concentration monitoring.
出处
《药学服务与研究》
CAS
CSCD
2011年第6期447-449,共3页
Pharmaceutical Care and Research
关键词
丙戊酸钠
血药浓度监测
酶增强免疫分析法
癫
sodium valproate
serum eoncenwation monitoring
enzyme-enhancement immunoassay
epilepsy
